196 related articles for article (PubMed ID: 22087801)
21. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
22. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
Moran M
PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
[TBL] [Abstract][Full Text] [Related]
23. Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases.
Sheean ME; Malikova E; Duarte D; Capovilla G; Fregonese L; Hofer MP; Magrelli A; Mariz S; Mendez-Hermida F; Nistico R; Leest T; Sipsas NV; Tsigkos S; Vitezic D; Larsson K; Sepodes B; Stoyanova-Beninska V
Drug Discov Today; 2020 Feb; 25(2):274-291. PubMed ID: 31704277
[TBL] [Abstract][Full Text] [Related]
24. Multidisciplinary approach to R&D in vitiligo, a neglected skin disease.
Valle Y; Lotti TM; Hercogova J; Schwartz RA; Korobko IV
Dermatol Ther; 2012; 25 Suppl 1():S1-9. PubMed ID: 23237032
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of implementing recommendations to improve neglected tropical diseases surveillance and response in Kenya: a modified Delphi study.
Ng'etich AKS; Voyi K; Mutero CM
BMC Health Serv Res; 2021 Oct; 21(1):1034. PubMed ID: 34598687
[TBL] [Abstract][Full Text] [Related]
26. "Creating hope" and other incentives for drug development for children.
Connor E; Cure P
Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
[TBL] [Abstract][Full Text] [Related]
27. Current trends in and future potential of crowdfunding to finance R&D of treatments for neglected tropical diseases.
Benazzouz SM; Malkinson J; Tóth G
Drug Discov Today; 2021 Jul; 26(7):1563-1568. PubMed ID: 33640317
[TBL] [Abstract][Full Text] [Related]
28. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
29. 360-degree Delphi: addressing sociotechnical challenges of healthcare IT.
Waldmüller H; Spreckelsen C; Rudat H; Krumm N; Rolke R; Jonas SM
BMC Med Inform Decis Mak; 2020 Jun; 20(1):101. PubMed ID: 32503609
[TBL] [Abstract][Full Text] [Related]
30. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
31. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
Tiwari J
Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
[TBL] [Abstract][Full Text] [Related]
32. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
33. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
34. Which Dimensions of Patient-Centeredness Matter? - Results of a Web-Based Expert Delphi Survey.
Zill JM; Scholl I; Härter M; Dirmaier J
PLoS One; 2015; 10(11):e0141978. PubMed ID: 26539990
[TBL] [Abstract][Full Text] [Related]
35. In silico repositioning of approved drugs for rare and neglected diseases.
Ekins S; Williams AJ; Krasowski MD; Freundlich JS
Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
[TBL] [Abstract][Full Text] [Related]
36. Financing R&D for neglected diseases.
Herrling PL
Nat Rev Drug Discov; 2009 Feb; 8(2):91. PubMed ID: 19189425
[No Abstract] [Full Text] [Related]
37. Orphan Drugs in Oncology.
Korchagina D; Jaroslawski S; Jadot G; Toumi M
Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
[TBL] [Abstract][Full Text] [Related]
38. The development of an internet-based outpatient cardiac rehabilitation intervention: a Delphi study.
Vandelanotte C; Dwyer T; Van Itallie A; Hanley C; Mummery WK
BMC Cardiovasc Disord; 2010 Jun; 10():27. PubMed ID: 20534167
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
[TBL] [Abstract][Full Text] [Related]
40. An exploration of factors related to dissemination of and exposure to internet-delivered behavior change interventions aimed at adults: a Delphi study approach.
Brouwer W; Oenema A; Crutzen R; de Nooijer J; de Vries NK; Brug J
J Med Internet Res; 2008 Apr; 10(2):e10. PubMed ID: 18417443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
